Drug Design, Development and Therapy (Aug 2021)
Transferrin-Decorated Protein-Lipid Hybrid Nanoparticle Efficiently Delivers Cisplatin and Docetaxel for Targeted Lung Cancer Treatment
Abstract
Kaiping Mao,1 Weina Zhang,2 Lan Yu,3 Yi Yu,1 Haixia Liu,1 Xiaotao Zhang3 1Department of Thoracic surgery, The Affiliated Hospital of Qingdao University, Qingdao, 266000, People’s Republic of China; 2Department of Plastic surgery, The Affiliated Hospital of Qingdao University, Qingdao, 266000, People’s Republic of China; 3Department of Cancer Stereotactic Radiotherapy, Affiliated Qingdao Central Hospital of Qingdao University, Qingdao, 266042, People’s Republic of ChinaCorrespondence: Xiaotao Zhang Tel +86 532-68667866Email [email protected]: Non-small cell lung cancer (NSCLC) therapy faces the barriers including drug resistance. A transferrin-functionalized protein-lipid hybrid nanoparticle (PLHN) was designed loading both cisplatin (CIS) and docetaxel (DTX) for the lung cancer treatment.Methods: CIS and DTX were loaded into the hybrid nanoparticle and then decorated with transferrin (Tf). The Tf-functionalized protein-lipid hybrid nanoparticle (Tf-CIS/DTX-PLHN) was investigated by determining the release behavior, cytotoxicity in vitro, and anticancer efficiency in vivo.Results: Tf-CIS/DTX-PLHN showed a nano-size of 189.5 ± 5.9 nm, and a surface tested to be − 16.9 ± 2.1 mV. Tf-CIS/DTX-PLHN exhibited obviously better antitumor ability in vitro and in vivo compared with the non Tf contained CIS and DTX co-loaded lipid nanoparticles (CIS/DTX-LN), single drug loaded nanoparticles, and free drugs.Conclusion: Since remarkable enhanced efficiency of Tf and synergistic effect of the drugs, it could inhibit the lung tumor growth and help with the lung cancer treatment.Keywords: lung cancer, hybrid nanoparticles, nanostructured lipid nanoparticles, protein nanoparticles, transferrin
